Cancer immunotherapy company CEL-SCI Corporation (NYSE American:CVM) said on Tuesday that the underwriters have announced the full exercise of 90,959 additional shares of common stock in over-allotment option in connection with its underwritten public offering.
The company had issued 606,395m shares of its common stock under its prior underwritten public offering.
Following the full exercise of the underwriters' over-allotment option, the company raised total gross proceeds from the offering of USD6.325m.
Aegis Capital Corp acted as the sole book-running manager for the offering.
CEL-SCI's lead investigational therapy Multikine is currently in a pivotal Phase 3 clinical trial involving head and neck cancer, for which the company has received Orphan Drug Status from the FDA.
FDA Advisory Committee votes in favour of GRAIL's Galleri multi-cancer early detection test
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
Clene Inc closes registered direct offering of common stock to existing shareholders
Insmed's ARIKAYCE sNDA granted priority review by FDA
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement